BioStem Technologies to Host Third Quarter 2025 Financial Results Conference Call on November 13, 2025
Rhea-AI Summary
BioStem Technologies (OTC: BSEM) will release its third quarter 2025 financial results on Thursday, November 13, 2025, and will host a conference call and webcast at 4:30 PM ET.
The webcast will feature an overview of the quarter from Jason Matuszewski, CEO, and Brandon Poe, CFO. Conference ID and dial-in numbers are provided for North America and international participants, and a live webcast link is available for online attendees.
Positive
- None.
Negative
- None.
News Market Reaction – BSEM
On the day this news was published, BSEM gained 4.48%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Conference call and webcast to be held at 4:30 PM ET
POMPANO BEACH, Fla., Oct. 30, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announces it will release its third quarter 2025 financial results on Thursday, November 13, 2025, and will host a conference call and webcast at 4:30 PM ET.
The webcast will feature an overview of the quarter from Jason Matuszewski, CEO, and Brandon Poe, CFO. To register for the event, please click HERE.
Conference Call & Webcast Information:
- Conference ID: 9695874
- North America Toll-Free: (800) 715-9871
- International Toll: +1 (646) 307-1963
- Webcast Link: https://events.q4inc.com/attendee/951812886
About BioStem Technologies, Inc. (OTC: BSEM): BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain® processing method. BioREtain® has been developed by applying the latest research in regenerative medicine, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (“AATB”). These systems and procedures are established in compliance with current Good Tissue Practices (“cGTP”) and current Good Manufacturing Processes (“cGMP”). Our portfolio of quality brands includes AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®. Each BioStem Technologies placental allograft is processed at the Company’s FDA registered and AATB accredited site in Pompano Beach, Florida. For more information visit biostemtechnologies.com and follow us on Twitter and Linkedin.
Join BioStem’s Distribution List & Social Media:
To follow the latest developments at BioStem, sign up for the Company’s email distribution list HERE, and follow us on X and LinkedIn.
Contact BioStem Technologies, Inc.:
Website: www.biostemtechnologies.com
E-Mail: info@biostemtech.com
X: @BSEM_Tech
Facebook: BioStemTechnologies
Phone: 954-380-8342
Investor Relations:
Philip Trip Taylor, Gilmartin Group
E-Mail: ir@biostemtech.com
FAQ
When will BioStem (BSEM) report third quarter 2025 results and hold the conference call?
Who will present on BioStem's Q3 2025 conference call for BSEM?
How can investors join the BioStem (BSEM) conference call on November 13, 2025?
Where can I watch the BioStem (BSEM) Q3 2025 webcast online?
Do I need to register to attend BioStem's November 13, 2025 webcast for BSEM?
What time zone is used for BioStem's November 13, 2025 conference call for BSEM?
